Mass Tort brief
Generic Price-Fixing Geopolitics and Specialized Formula Liability Settlements
Pharma titan Teva seeks protection from anti-Israel jury bias while Abbott Laboratories caps infant formula litigation with a $670M resolution.
Mass Tort
Abbott's $670M deal resolves its most dangerous formula verdict — capping multi-year exposure and resetting liability expectations across the pediatric nutrition industry.
BackgroundParents filed hundreds of product liability lawsuits alleging Abbott's specialty formulas caused necrotizing enterocolitis, a severe intestinal disease in premature infants. Abbott maintained its specialized clinical products met pediatric standards and remained vital for premature infant survival.
- The comprehensive $670 million agreement resolves approximately 2,000 pending preterm formula claims across state and federal courts, settling extensive legal exposure for Abbott.
- The deal resolves the prominent Gill family lawsuit in Missouri, which had resulted in a $495 million jury verdict that was rapidly accumulating post-judgment interest.
- Abbott secured victories in all three federal bellwether trials before reaching this private compromise, establishing strong leverage ahead of negotiating final settlement terms.
Mass Tort
Teva is attempting to mask its Israeli origin in court — seeking to insulate a critical price-fixing trial from mounting geopolitical backlash.
BackgroundTeva faces a major antitrust trial initiated by health insurer Humana over generic drug price coordination across US distribution networks. As one of Israel's largest public corporations, Teva's valuation significantly moves Tel Aviv stock indices and domestic pension funds.
- Teva's legal team filed the pre-trial motion in Philadelphia federal district court ahead of a September 15 generic drug price-fixing trial, attempting to restrict plaintiff disclosures.
- The motion requests that plaintiffs be barred from referencing Teva's Tel Aviv headquarters or Israeli roots, citing risk that public political sentiment could prejudice potential jurors.
- The underlying antitrust litigation stems from broad allegations by Humana that major generic drug manufacturers coordinated prices, exposing Teva to substantial financial liabilities.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
